SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours.
about
Tricyclic [1,2,4]triazine 1,4-dioxides as hypoxia selective cytotoxinsGreen fluorescent protein is a suitable reporter of tumor hypoxia despite an oxygen requirement for chromophore formationRadical properties governing the hypoxia-selective cytotoxicity of antitumor 3-amino-1,2,4-benzotriazine 1,4-dioxides.Isotopic labeling experiments that elucidate the mechanism of DNA strand cleavage by the hypoxia-selective antitumor agent 1,2,4-benzotriazine 1,4-di-N-oxideToward hypoxia-selective DNA-alkylating agents built by grafting nitrogen mustards onto the bioreductively activated, hypoxia-selective DNA-oxidizing agent 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine).Tirapazamine: a bioreductive anticancer drug that exploits tumour hypoxia.Improved potency of the hypoxic cytotoxin tirapazamine by DNA-targeting.Hypoxia-inducible regulation of a prodrug-activating enzyme for tumor-specific gene therapy.Six degrees of separation: the oxygen effect in the development of radiosensitizers.Motexafin gadolinium: a possible new radiosensitiser.DNA strand cleaving properties and hypoxia-selective cytotoxicity of 7-chloro-2-thienylcarbonyl-3-trifluoromethylquinoxaline 1,4-dioxide.Enzyme mechanism-based, oxidative DNA-protein cross-links formed with DNA polymerase β in vivoDetection of hypoxia by measurement of DNA damage in individual cells from spheroids and murine tumours exposed to bioreductive drugs. I. Tirapazamine.Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugsTirapazamine-induced DNA damage measured using the comet assay correlates with cytotoxicity towards hypoxic tumour cells in vitro.Hypoxia in head and neck cancer: how much, how important?Prospects for bioreductive drug development.Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent.Tirapazamine: hypoxic cytotoxicity and interaction with radiation as assessed by the micronucleus assayThe in situ tumour response to combinations of cyclophosphamide and tirapazamine.Recent developments in the design of bioreductive drugsOverexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069Knock-down of hypoxia-induced carbonic anhydrases IX and XII radiosensitizes tumor cells by increasing intracellular acidosisCisplatin anti-tumour potentiation by tirapazamine results from a hypoxia-dependent cellular sensitization to cisplatinDoes reductive metabolism predict response to tirapazamine (SR 4233) in human non-small-cell lung cancer cell lines?The concurrent chemoradiation paradigm--general principles.Involvement of decreased hypoxia-inducible factor 1 activity and resultant G1-S cell cycle transition in radioresistance of perinecrotic tumor cells.Targeting hypoxia cell signaling for cancer therapy.Hypoxia-specific drug tirapazamine does not abrogate hypoxic tumor cells in combination therapy with irinotecan and methylselenocysteine in well-differentiated human head and neck squamous cell carcinoma a253 xenografts.Hypoxic regulation of glucose transport, anaerobic metabolism and angiogenesis in cancer: novel pathways and targets for anticancer therapeutics.Current molecular design of intelligent drugs and imaging probes targeting tumor-specific microenvironments.Novel imaging approaches to head and neck cancerAssessment of tissue redox status using metabolic responsive contrast agents and magnetic resonance imaging.Hypoxia-activated cytotoxic agent tirapazamine enhances hepatic artery ligation-induced killing of liver tumor in HBx transgenic mice.DNA Adducts from Anticancer Drugs as Candidate Predictive Markers for Precision Medicine.Hypoxia and hypoxia-inducible factors: master regulators of metastasis.Targeting tumor hypoxia in nasopharyngeal carcinoma.Development of novel benzotriazines for drug discovery.Overcoming the Achilles' heel of photodynamic therapy.On The Latest Three-Stage Development of Nanomedicines based on Upconversion Nanoparticles.
P2860
Q24651122-2AC4F18E-4BC4-4AE1-A694-95A40C4B8684Q28344477-A2E0A7DD-C68F-4527-B2EB-9F3E61C9DB06Q30990659-227EBBA8-4C63-416C-8E7C-281B37CF6459Q33575435-A3A2A920-BC3E-4161-A17C-E0038C723967Q34061361-54413AC6-93B4-415F-87DE-788E6D0F677EQ34090988-98E8166B-1F1A-41D4-B944-177C048BA501Q34139877-8E410338-F171-4A32-82F1-7954B0A8BC28Q34775024-CFE2C095-CABD-44B3-BEED-47D03A30B95AQ35116798-80E150F3-56B5-4F77-A6E1-EA36A4AD0D9EQ35164769-0D381704-759D-4874-83F6-67E4F99ADBFAQ35707721-5575C48C-861D-4904-98A9-274B96C65E4FQ35865649-57708B75-3593-47FE-84D0-63C82A9D7576Q36080580-94E7159D-E0F6-4555-B79E-7F29BF65516EQ36115429-6B2B4E02-CE77-4D72-97E3-E1F5C089F3C7Q36138622-8C3141AF-B037-4885-AC33-218B6FB2D90DQ36160990-FABA9140-EB44-4AAD-A634-DA7F7B97C71CQ36181210-16EF1FC7-7DA6-4F15-979E-2CB69F2AE53DQ36245361-C6E744EB-2205-431B-BD70-B298A539675CQ36291894-A066B5A9-0EE7-4078-9314-4C4A52444860Q36291926-6791B202-223A-431F-BD29-72EACEC91937Q36292017-78114C08-F516-4D59-9866-5BE683BD65FCQ36431422-8E18C7A5-ED56-4C70-A3D2-3B3D6CDB0C53Q36516789-39E6867D-7A24-4170-81C7-DD3DE1B4BF21Q36618010-D2B6AFBC-657A-45A7-A4EC-6780FDE099BCQ36641035-B0A5A770-FC0C-4A49-97D7-E9E5887857EFQ36720868-61172FA2-6E87-4D4F-AA3E-422EF1918AD6Q36780880-6B7DE2C4-8433-4C5D-9ECE-F19758554D46Q36784388-F07231D4-2AD2-4412-9F34-62EBD8D09B54Q36787650-D6066F7F-818B-49DE-8555-D651C1F83E4AQ36862390-FB1B277F-930D-4300-89D1-54F41E59FF8BQ37001393-5363C985-CDCA-4E17-AB04-07958AFBB224Q37012938-0AE60E69-74DC-4F10-B148-AB914E47FF7BQ37222800-E7C443F4-D4A6-409F-BE84-F1B7A458B3CAQ37369324-82C1D9B5-64FC-46CC-8536-508C176D656CQ37736567-4015BF52-447F-4A1F-9D4D-59AED558B8A9Q37801762-FEFFBC9B-D29A-4BD4-A3A1-39567AB4597DQ37959387-9A87FDAC-E80F-4627-BBB6-64E555AF87BBQ38088317-55DF56D4-949C-4AA2-8D9B-B37B6362F2F6Q38813185-A7C996CA-5E05-4490-A47E-8ADCFDCDD1AAQ38887908-00801270-AF63-44C2-B87D-69241B0C3B4E
P2860
SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
1993年论文
@zh
1993年论文
@zh-cn
name
SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours.
@ast
SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours.
@en
type
label
SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours.
@ast
SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours.
@en
prefLabel
SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours.
@ast
SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours.
@en
P2860
P356
P1476
SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours.
@en
P2093
P2860
P2888
P304
P356
10.1038/BJC.1993.220
P407
P577
1993-06-01T00:00:00Z